Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- 43% Lower Mortality Seen in Colorectal Screening Participants (HCP Live)
- BioNTech halts mRNA colorectal cancer vaccine trial after safety review (Reuters)
- Microdroplets may reduce colorectal tumor growth at potentially lower cost (Medical Xpress)
- What it takes to build a gut-health service line (GI & Hepatology News)
- Weight Down, Steps Down: The GLP-1 Catch (Medscape)
- Pediatric Gastroenterology Faces AI Reality Check (Medscape)
- Ayble Health Joins Amazon’s Health Benefits Connector to expand Virtual GI Care Access to Millions of Americans (PR Newswire)
- Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening (Guardant Health)
